Insufficient production capacity, the two national collection products actively withdrawn from the Internet

On August 18, Gansu Province Pharmaceutical and Medical Consumption Purchasing Network issued an announcement saying that 42 drugs for 32 companies applied for dismissal drugs. These varieties involve different channels such as national collection and Gansu Province sunshine procurement platform.

The Jianzhi Bureau sorted out and found that: the national collection of varieties, Yichang Renfang Fudi Pharmaceutical's acetyl amino phenol tablets and Guangdong East Sunshine Pharmaceutical hydrochloric acid tablets are actively revoked the qualifications of hanging nets on the grounds of "insufficient enterprise production capacity".

In addition, the supply of penicillin sodium and Ronicillin capsules from 2017 to 2018 also had supply problems. Gansu records a penalty for a bad record of Jiangxi Dongfeng Pharmaceutical Co., Ltd. and Suzhou Erye Pharmaceutical Co., Ltd., respectively.

Although Gansu has issued reminders: The above -mentioned removal varieties, 35 of which have the same variety of pangic drugs to ensure supply, and there are 7 pharmaceutical platforms without winning the bid, and the overall clinical application is not affected. However, the problem of "insufficient production capacity" in the national collection varieties is still rare.

Renfu Pharmaceutical said to Jianzhi Bureau: Previously, the subsidiary Yichang Renfu provided two specifications: 0.5g*100 tablets and 0.5G*10 tablets to Gansu Pharmaceutical Recruitment Platform. 10 pieces of boxes. The procurement platform has the same specifications of the same specifications to ensure supply. Enterprises have not been punished.

Although it is a false alarm, the national collection of drugs cannot guarantee the shadow of supply, but it has always been there.

The collection of varieties actively withdraw the net, the two pharmaceutical companies have their own hidden feelings

The acetylphenols and Missishaxin tablets that were notified this time belonged to the second batch of collection in the country.

In January 2020, Shanghai Sunshine Procurement Network announced the results of the second batch of drug collection in the country: acetyl aminophenol tablets by Chengdu Tongde, Huazhong Pharmaceutical, Chengdu Landao, Yichang Renfu, Sichuan Tongyuan, Heng Heng 6, Heng 6 Family companies win the bid. Missishaxyl Hydrochloride was shortlisted by five companies, East Sunshine Pharmaceutical, Sichuan State, Nanjing Shenghe, Chongqing Winchi, and Bayer.

According to the region, Yichang Renfu is responsible for providing Gansu with the supply responsibility for the supply of acetylphenol, and the supply responsibility of Mississashaxide tablets in Nanjing. According to the rules, the selected enterprises are 4 or more, and the collection cycle is in principle for 3 years. This means that this group of national collection will not be considered a purchase cycle until April 2023.

The withdrawal of Gansu varieties this time is the initiative to apply for the enterprise, so it is surprising. Since it is a national collection of varieties, how can we say that it is suspended?

The variety of human blessings has only replaced the packaging specifications and does not affect actual use. However, the treatment of Moxisha star tablets of hydrochloride did not explain to the outside world clearly. According to the second batch of winning bid results: the bidding enterprise of Moishaxing tablets in Gansu is Nanjing Shenghe, but this time it proposes to withdraw from the network is Dongxiang Pharmaceutical, the reason is also "insufficient production capacity of the enterprise."

Jianzhi Bureau tried to contact the Gansu bidding and procurement platform, and the phone has not been able to connect.

Among the second batch of episodes, the east -sun -sung -sung -hydrochloric acid tablets are also selected. The provinces are seven provinces and cities in Beijing, Jilin, Shanghai, Jiangxi, Hubei, Guangdong, and Guizhou. Why does the supplier of Mosha star change from Nanjing Shenghe to East Sunshine? The announcement did not give a clear instruction.

People in the industry believe that Dongguang Pharmaceuticals may be a "substitute" identity, so the withdrawal from the net is exempted from processing.

The collection and breaking supply frequently occur, and the monitoring must also ensure the profit of pharmaceutical companies

After winning the bid, the price of drugs has been greatly reduced, and the industrial chain has also changed. Enterprises should ensure production capacity and profit margins, and expand the scale of production and reduce costs, which will directly affect the "confidence" of the enterprise's quotation when participating in the collection.

In August 2020, the National Organization Pharmaceutical Cooperative Procurement Office announced that North China Pharmaceuticals failed to procure the agreed volume in Shandong Province in accordance with the agreement. Cancel eligibility.

Since then, whether it is the country or the local area, the relevant departments have stepped up the monitoring of the supply of collecting varieties.

In November 2020, the Beijing Pharmaceutical Sunshine Procurement Platform released news. The Pharma Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Calcium tablets could not be supplied in a short period of time, an increase of 3 months of transition period.

Almost at the same time, the Hubei Provincial Medical Insurance Bureau issued a notice that Sam Dershon's collection of chopandarta potassium (50mg) was disconnected and will be replaced by Huahai Pharmaceutical.

In fact, insufficient production capacity leads to the unable to ensure reasonable profits, which is the main reason for product confession. For a long time, the problem of high prices of Chinese drugs is serious. The price of generic drugs is 2-3 times the average price of major international countries. Even if there is no large-scale effect on sales, pharmaceutical companies can still make profit.

The industry generally believes that the prices of drugs after national collection have been significantly reduced, and marketing costs return to a relatively reasonable level. Only by continuously expanding production scale and robbing most of the market share can pharmaceutical companies survive.

Obviously, the increasingly "inner volume" collection quotation has been valued by relevant departments. The State Drug Administration has mentioned many times in public that drug production enterprises "should be rationally quoted and the order of ordering the orderly competition in the industry and the environment of sustainable development."

The State Medical Insurance Bureau also believes that collecting and minimum prices are not pursued and resolutely opposed to running bidding, and we must achieve a diversified dynamic goal balance.

Obviously, the original intention of the national collection is: "patient -centered" to let Chinese patients use good medicines for good quality.The Chinese pharmaceutical industry is in a critical period of transformation, and all parties need to work together.Writing ｜ Lei Gong

Edit ｜ Jiang Yun Jia Ting

Operation ｜ Valley

Photo Source ｜ Visual China

#采 ## ###

- END -